Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease
stevepb / Pixabay

Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease

A new clinical trial which will test a two-part combination treatment for Erdheim-Chester disease was recently added to the clinicaltrials.gov website. This trial will be specifically for patients with BRAF…

Continue Reading Clinical Trial Will Test Combination Treatment for Erdheim-Chester Disease
Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial
source: pixabay.com

Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Prader-Willi Syndrome (PWS) is caused by deleted genes on chromosome 15. This results in improper signaling of satiety, leading to obesity. Individuals with the condition can suffer from respiratory/cardiac disease, gastric…

Continue Reading Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Myasthenia Gravis (MG) is a progressive autoimmune disorder which results in the weakening of muscles. Most people with the condition are able to manage their symptoms with treatment and have…

Continue Reading Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online
Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial
Aymanejed / Pixabay

Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial

According to a story from drugs.com, the biopharmaceutical company Catabasis pharmaceuticals recently provided updates on the status of its Phase 3 clinical trial testing its investigational therapy CAT-1004, also known…

Continue Reading Company Provides Updates for Phase 3 Duchenne Muscular Dystrophy Trial
New Research Seeks to Learn More About Bronchiectasis to Guide Treatment
mwooten / Pixabay

New Research Seeks to Learn More About Bronchiectasis to Guide Treatment

A new bronchiectasis research study was added to the clinicaltrials.gov website on New Years Day. This observational study, called the BRIDGE Study (Bronchiectasis Research Involving Databases, Genomics, and Endotyping) is…

Continue Reading New Research Seeks to Learn More About Bronchiectasis to Guide Treatment

Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation

Limb Girdle Muscular Dystrophy Type 2D (LGMD2D), also called alpha-sarcoglycanopathy, is a form of muscular dystrophy which is caused by a defected SGCA gene. It causes the body to lose function of…

Continue Reading Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases

According to a story from ksl.com, a recent poll found that the majority of Americans are in support of using gene editing technology in order to protect newborns from genetic…

Continue Reading Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases

Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial

According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…

Continue Reading Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial